Forsteo licensed for use in men

The licence for Forsteo (teriparatide) has been extended to include the treatment of osteoporosis in men at increased risk of fracture.

The recommended dose is 20 micrograms administered once daily by subcutaneous injection in the thigh or abdomen.

Further information: Lilly 01256 315000

Go to: MIMS drug entry for Forsteo

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more